Physician profile
Patrick Hynes
NPI 1972582104
$1,043.76
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $66.31 · 2021: $326 · 2022: $192 · 2023: $233 · 2024: $36.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $269.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $221.05 | 2021 | |
| Ironshore Pharmaceuticals INC. | $196.88 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $149.55 | 2021-2023 | |
| Glaxosmithkline, LLC. | $143.54 | 2019-2023 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $79.21 | 2019-2021 | |
| Pfizer INC. | $68.75 | 2019-2023 | |
| Tris Pharma INC | $64.59 | 2022-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $52.34 | 2019-2022 | |
| Adlon Therapeutics L.P. | $23.31 | 2019-2020 | |
| Dermira, INC. | $19.07 | 2021 | |
| Shire North American Group INC | $12.96 | 2019 | |
| Genentech USA, INC. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.